Sucampo Pharmaceuticals (SCMP) Upgraded to Buy by BidaskClub

BidaskClub upgraded shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) from a hold rating to a buy rating in a report published on Tuesday morning.

Several other research firms have also recently commented on SCMP. Maxim Group reaffirmed a buy rating and issued a $23.00 price target on shares of Sucampo Pharmaceuticals in a report on Thursday, November 2nd. Leerink Swann initiated coverage on Sucampo Pharmaceuticals in a report on Monday, August 21st. They issued an outperform rating and a $15.00 price target for the company. Zacks Investment Research raised Sucampo Pharmaceuticals from a hold rating to a buy rating and set a $11.00 price target for the company in a report on Tuesday, October 17th. initiated coverage on Sucampo Pharmaceuticals in a report on Wednesday, November 15th. They issued a buy rating and a $14.00 price target for the company. Finally, ValuEngine raised Sucampo Pharmaceuticals from a hold rating to a buy rating in a report on Friday, December 1st. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $16.40.

Sucampo Pharmaceuticals (SCMP) opened at $14.20 on Tuesday. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. The company has a market capitalization of $627.25, a P/E ratio of 9.21, a price-to-earnings-growth ratio of 4.00 and a beta of 1.47. Sucampo Pharmaceuticals has a twelve month low of $9.30 and a twelve month high of $17.24.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.25 by $0.02. The firm had revenue of $61.27 million during the quarter, compared to analysts’ expectations of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.30 EPS. equities research analysts expect that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current year.

In other news, major shareholder Sachiko Kuno sold 1,000,000 shares of the stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $12.00, for a total value of $12,000,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.13% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. HPM Partners LLC acquired a new position in shares of Sucampo Pharmaceuticals in the 2nd quarter worth approximately $1,307,000. Louisiana State Employees Retirement System grew its position in Sucampo Pharmaceuticals by 1.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 100 shares during the last quarter. Trexquant Investment LP bought a new stake in Sucampo Pharmaceuticals during the 3rd quarter worth approximately $122,000. Nine Chapters Capital Management LLC bought a new stake in Sucampo Pharmaceuticals during the 3rd quarter worth approximately $127,000. Finally, JPMorgan Chase & Co. bought a new stake in Sucampo Pharmaceuticals during the 2nd quarter worth approximately $117,000. 65.31% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://stocknewstimes.com/2017/12/06/sucampo-pharmaceuticals-scmp-upgraded-to-buy-by-bidaskclub.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply